Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 9513037, 14 pages
http://dx.doi.org/10.1155/2016/9513037
Review Article

miR-155 as a Biomarker in B-Cell Malignancies

1Department of Haematology, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark
2Department of Haematology, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Aarhus C, Denmark
3Department of Mathematical Sciences, Aalborg University, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark
4Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark
5Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark

Received 23 December 2015; Accepted 3 April 2016

Academic Editor: Stefan Costinean

Copyright © 2016 Hanne Due et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein, and E. S. Jaffe, “The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications,” Blood, vol. 117, no. 19, pp. 5019–5032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. National Research Council (US) Committee on a Framework for Developing a New Taxonomy of Disease, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease, National Academies Press (US), Washington, DC, USA, 2011.
  3. Biomarkers Definitions Working Group, “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. S. Pepe, H. Janes, G. Longton, W. Leisenring, and P. Newcomb, “Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker,” American Journal of Epidemiology, vol. 159, no. 9, pp. 882–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Lan, H. Lu, X. Wang, and H. Jin, “MicroRNAs as potential biomarkers in cancer: opportunities and challenges,” BioMed Research International, vol. 2015, Article ID 125094, 17 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Xu, Z. Cao, W. Liu et al., “Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: a multicenter study,” Annals of Surgery, 2015. View at Publisher · View at Google Scholar
  7. H. Ding, Z. Huang, M. Chen et al., “Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease,” Parkinsonism & Related Disorders, vol. 22, pp. 68–73, 2015. View at Publisher · View at Google Scholar
  8. S. C. Marques, M. B. Laursen, J. S. Bødker et al., “MicroRNAs in B-cells: from normal differentiation to treatment of malignancies,” Oncotarget, vol. 6, no. 1, pp. 7–25, 2015. View at Google Scholar · View at Scopus
  9. L. K. Jørgensen, M. Ø. Poulsen, M. B. Laursen et al., “MicroRNAs as novel biomarkers in diffuse large B-Cell lymphoma—a systematic review,” Danish Medical Journal, vol. 62, no. 5, Article ID A5048, 2015. View at Google Scholar · View at Scopus
  10. M. D. Jansson and A. H. Lund, “MicroRNA and cancer,” Molecular Oncology, vol. 6, no. 6, pp. 590–610, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Xue, L.-M. Hua, M. Guo, and J.-M. Luo, “SHIP1 is targeted by miR-155 in acute myeloid leukemia,” Oncology Reports, vol. 32, no. 5, pp. 2253–2259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Huang, J. Luo, Q. Cai et al., “MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3,” International Journal of Cancer, vol. 128, no. 8, pp. 1758–1769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Mashima, “Physiological roles of miR-155,” Immunology, vol. 145, no. 3, pp. 323–333, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Musilova and M. Mraz, “MicroRNAs in B-cell lymphomas: how a complex biology gets more complex,” Leukemia, vol. 29, no. 5, pp. 1004–1017, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. R. W. Georgantas III, R. Hildreth, S. Morisot et al., “CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 8, pp. 2750–2755, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore, “MicroRNA-155 is induced during the macrophage inflammatory response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 5, pp. 1604–1609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Ceppi, A. M. Pereira, I. Dunand-Sauthier et al., “MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2735–2740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. T.-H. Thai, D. P. Calado, S. Casola et al., “Regulation of the germinal center response by MicroRNA-155,” Science, vol. 316, no. 5824, pp. 604–608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Zhang, J. He, F. Zhang et al., “Prognostic role of microRNA-155 in various carcinomas: results from a meta-analysis,” Disease Markers, vol. 34, no. 6, pp. 379–386, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. I. A. Babar, C. J. Cheng, C. J. Booth et al., “Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 26, pp. E1695–E1704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” PLoS Medicine, vol. 6, no. 7, Article ID e1000100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. M. O'Connell, A. A. Chaudhuri, D. S. Rao, and D. Baltimore, “Inositol phosphatase SHIP1 is a primary target of miR-155,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7113–7118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Costinean, S. K. Sandhu, I. M. Pedersen et al., “Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice,” Blood, vol. 114, no. 7, pp. 1374–1382, 2009. View at Publisher · View at Google Scholar
  24. G. Teng, P. Hakimpour, P. Landgraf et al., “MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase,” Immunity, vol. 28, no. 5, pp. 621–629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Vigorito, K. L. Perks, C. Abreu-Goodger et al., “microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells,” Immunity, vol. 27, no. 6, pp. 847–859, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. N. Dagan, X. Jiang, S. Bhatt, E. Cubedo, K. Rajewsky, and I. S. Lossos, “miR-155 regulates HGAL expression and increases lymphoma cell motility,” Blood, vol. 119, no. 2, pp. 513–520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Rai, S.-W. Kim, M. R. McKeller, P. L. M. Dahia, and R. C. T. Aguiar, “Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3111–3116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Tili, J.-J. Michaille, A. Cimino et al., “Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock,” The Journal of Immunology, vol. 179, no. 8, pp. 5082–5089, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. L.-F. Lu, T.-H. Thai, D. P. Calado et al., “Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein,” Immunity, vol. 30, no. 1, pp. 80–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. H. Sehn, J. Donaldson, M. Chhanabhai et al., “Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5027–5033, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Vaidya and T. E. Witzig, “Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era,” Annals of Oncology, vol. 25, no. 11, pp. 2124–2133, 2014. View at Publisher · View at Google Scholar
  32. H. Zhong, L. Xu, J.-H. Zhong et al., “Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma,” Experimental and Therapeutic Medicine, vol. 3, no. 5, pp. 763–770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. C. H. Lawrie, J. Chi, S. Taylor et al., “Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma,” Journal of Cellular and Molecular Medicine, vol. 13, no. 7, pp. 1248–1260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C. H. Lawrie, S. Soneji, T. Marafioti et al., “MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma,” International Journal of Cancer, vol. 121, no. 5, pp. 1156–1161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. C. H. Lawrie, S. Gal, H. M. Dunlop et al., “Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 141, no. 5, pp. 672–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Roehle, K. P. Hoefig, D. Repsilber et al., “MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas,” British Journal of Haematology, vol. 142, no. 5, pp. 732–744, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Fang, D.-X. Zhu, H.-J. Dong et al., “Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma,” Annals of Hematology, vol. 91, no. 4, pp. 553–559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Di Lisio, M. Sánchez-Beato, G. Gómez-López et al., “MicroRNA signatures in B-cell lymphomas,” Blood Cancer Journal, vol. 2, no. 2, article e57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Iqbal, Y. Shen, X. Huang et al., “Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma,” Blood, vol. 125, no. 7, pp. 1137–1145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Zajdel, G. Rymkiewicz, M. Chechlinska et al., “miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma,” Tumor Biology, vol. 36, no. 7, pp. 5377–5388, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. A. A. Alizadeh, M. B. Elsen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Rosenwald, G. Wright, W. C. Chan et al., “The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 25, pp. 1937–1947, 2002. View at Publisher · View at Google Scholar
  44. W. W. L. Choi, D. D. Weisenburger, T. C. Greiner et al., “A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy,” Clinical Cancer Research, vol. 15, no. 17, pp. 5494–5502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. J. A. Read, J. L. Koff, L. J. Nastoupil, J. N. Williams, J. B. Cohen, and C. R. Flowers, “Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms,” Clinical Lymphoma, Myeloma and Leukemia, vol. 14, no. 6, pp. 460.e2–467.e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Caramuta, L. Lee, D. M. Özata et al., “Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma,” Blood Cancer Journal, vol. 3, no. 10, article e152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Fischer, M. Hummel, A. Korfel, D. Lenze, K. Joehrens, and E. Thiel, “Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas,” Neuro-Oncology, vol. 13, no. 10, pp. 1090–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Kluiver, S. Poppema, D. de Jong et al., “BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas,” The Journal of Pathology, vol. 207, no. 2, pp. 243–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. J.-L. Robertus, G. Harms, T. Blokzijl et al., “Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma,” Modern Pathology, vol. 22, no. 4, pp. 547–555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Huskova, K. Korecka, J. Karban et al., “Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas,” International Journal of Hematology, vol. 102, no. 4, pp. 441–450, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. P. S. Eis, W. Tam, L. Sun et al., “Accumulation of miR-155 and BIC RNA in human B cell lymphomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 10, pp. 3627–3632, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Go, J.-Y. Jang, P.-J. Kim et al., “MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma,” Oncotarget, vol. 6, no. 17, pp. 15035–15049, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Imig, N. Motsch, J. Y. Zhu et al., “microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma,” Nucleic Acids Research, vol. 39, no. 5, pp. 1880–1893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Tuo, D. Shen, H. H. Yang, and C.-C. Chan, “Distinct MicroRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis,” American Journal of Ophthalmology, vol. 157, no. 3, pp. 728–734, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Zhang, K. Nie, and W. Tam, “BIC is processed efficiently to microRNA-155 in Burkitt lymphoma cells,” Leukemia, vol. 22, no. 9, pp. 1795–1797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Kluiver, E. Haralambieva, D. De Jong et al., “Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma,” Genes Chromosomes and Cancer, vol. 45, no. 2, pp. 147–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Metzler, M. Wilda, K. Busch, S. Viehmann, and A. Borkhardt, “High expression of precursor MicroRNA-155/BIC RNA in children with burkitt lymphoma,” Genes Chromosomes and Cancer, vol. 39, no. 2, pp. 167–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Jones, J. P. Nourse, C. Keane, A. Bhatnagar, and M. K. Gandhi, “Plasma microRNA are disease response biomarkers in classical hodgkin lymphoma,” Clinical Cancer Research, vol. 20, no. 1, pp. 253–264, 2014. View at Publisher · View at Google Scholar
  59. C. Thorns, J. Kuba, V. Bernard et al., “Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma,” Virchows Archiv, vol. 460, no. 4, pp. 371–377, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Cai, X. Liu, J. Cheng et al., “MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 4, pp. 523–531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Saito, H. Suzuki, H. Tsugawa et al., “Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication,” PLoS ONE, vol. 7, no. 11, Article ID e47396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Takei, N. Ohnishi, M. Kisaka, and K. Mihara, “Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas,” SpringerPlus, vol. 3, article 288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Peveling-Oberhag, G. Crisman, A. Schmidt et al., “Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection,” Leukemia, vol. 26, no. 7, pp. 1654–1662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. A. J. Arribas, C. Gómez-Abad, M. Sánchez-Beato et al., “Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling,” Modern Pathology, vol. 26, no. 7, pp. 889–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Bouteloup, A. Verney, N. Rachinel et al., “MicroRNA expression profile in splenic marginal zone lymphoma,” British Journal of Haematology, vol. 156, no. 2, pp. 279–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. C. H. Lawrie, E. Ballabio, O.-J. Dyar et al., “MicroRNA expression in chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 147, no. 3, pp. 398–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. D.-X. Zhu, W. Zhu, C. Fang et al., “MiR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes,” Carcinogenesis, vol. 33, no. 7, pp. 1294–1301, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Marton, M. R. Garcia, C. Robello et al., “Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis,” Leukemia, vol. 22, no. 2, pp. 330–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Y. Yeh, H. G. Ozer, A. M. Lehman et al., “Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling,” Blood, vol. 125, no. 21, pp. 3297–3305, 2015. View at Publisher · View at Google Scholar
  70. K. Vargova, N. Curik, P. Burda et al., “MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia,” Blood, vol. 117, no. 14, pp. 3816–3825, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. C. P. Pallasch, M. Patz, Y. Jung Park et al., “miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia,” Blood, vol. 114, no. 15, pp. 3255–3264, 2009. View at Publisher · View at Google Scholar
  72. S. Li, H. F. Moffett, J. Lu et al., “Microrna expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells,” PLoS ONE, vol. 6, no. 3, Article ID e16956, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. V. Fulci, S. Chiaretti, M. Goldoni et al., “Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia,” Blood, vol. 109, no. 11, pp. 4944–4951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Ferrajoli, T. D. Shanafelt, C. Ivan et al., “Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia,” Blood, vol. 122, no. 11, pp. 1891–1899, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Jung and R. C. T. Aguiar, “MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 144, no. 1, pp. 138–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. T. L. Parker and M. P. Strout, “Chronic lymphocytic leukemia: prognostic factors and impact on treatment,” Discovery Medicine, vol. 11, no. 57, pp. 115–123, 2011. View at Google Scholar · View at Scopus
  77. R. Visone, L. Z. Rassenti, A. Veronese et al., “Karyotype-specific microRNA signature in chronic lymphocytic leukemia,” Blood, vol. 114, no. 18, pp. 3872–3879, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Rossi, M. Shimizu, E. Barbarotto et al., “MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival,” Blood, vol. 116, no. 6, pp. 945–952, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Guinn, A. S. Ruppert, K. Maddocks et al., “miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib,” Leukemia, vol. 29, no. 5, pp. 1210–1213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Wang, L. P. Tan, M. K. Dijkstra et al., “miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression,” The Journal of Pathology, vol. 215, no. 1, pp. 13–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Cui, L. Chen, S. Zhang et al., “Micro RNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia,” Blood, vol. 124, no. 4, pp. 546–554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. A. E. Rodriguez, J. A. Hernandez, M. Hernandez et al., “Chronic lymphocytic leukemia (CLL) with a high number of losses in 13Q is associated with different biological features,” Laboratory Investigation, vol. 93, article 358A, 2013. View at Google Scholar
  83. B. Eichhorst, T. Robak, E. Montserrat et al., “Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 26, supplement 5, Article ID mdv303, pp. v50–v54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Ruskoné-Fourmestraux, A. Lavergne, P. H. Aegerter et al., “Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment,” Gut, vol. 48, no. 3, pp. 297–303, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Zhang, A. M. Roccaro, C. Rombaoa et al., “LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas,” Blood, vol. 120, no. 8, pp. 1678–1686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. M. M. Fabani, C. Abreu-Goodger, D. Williams et al., “Efficient inhibition of miR-155 function in vivo by peptide nucleic acids,” Nucleic Acids Research, vol. 38, no. 13, pp. 4466–4475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. C. J. Cheng, R. Bahal, I. A. Babar et al., “MicroRNA silencing for cancer therapy targeted to the tumour microenvironment,” Nature, vol. 518, no. 7537, pp. 107–110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. J. H. Kim, W. S. Kim, and C. Park, “Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1,” Leukemia and Lymphoma, vol. 53, no. 8, pp. 1586–1591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Rai, S. Karanti, I. Jung, P. L. M. Dahia, and R. C. T. Aguiar, “Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma,” Cancer Genetics and Cytogenetics, vol. 181, no. 1, pp. 8–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. H. D. Munch-Petersen, U. Ralfkiaer, L. D. Sjö et al., “Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-Cell lymphoma,” Applied Immunohistochemistry and Molecular Morphology, vol. 23, no. 3, pp. 188–195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. A. E. Rodríguez, J. Á. Hernández, R. Benito et al., “Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14,” PLoS ONE, vol. 7, no. 11, Article ID e48485, 2012. View at Publisher · View at Google Scholar
  92. G. A. Calin, M. Ferracin, A. Cimmino et al., “A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 353, no. 17, pp. 1793–1801, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Li, P. Smyth, R. Flavin et al., “Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells,” BMC Biotechnology, vol. 7, article 36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. M. S. Pepe, R. Etzioni, Z. Feng et al., “Phases of biomarker development for early detection of cancer,” Journal of the National Cancer Institute, vol. 93, no. 14, pp. 1054–1061, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. National Library of Medicine (US), “Trametinib and Akt inhibitor GSK2141795 in treating patients with acute myeloid leukemia,” ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, 2015.
  96. miRagen Therapeutics, “Safety, tolerability and pharmacokinetic study of MRG-106 in patients with cutaneous T cell lymphoma (CTCL), MF subtype,” in ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, 2015. View at Google Scholar
  97. E. S. Hildebrandt-Eriksen, Y. Z. Bagger, T. B. Knudsen et al., “A unique therapy for HCV inhibits microRNA-122 in humans and results in HCV RNA suppression in chronically infected chimpanzees: results from primate and first-in-human studies,” Hepatology, vol. 50, no. 6, p. LB19, 2009. View at Google Scholar
  98. V. Manfè, E. Biskup, A. Rosbjerg et al., “MiR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma,” PLoS ONE, vol. 7, no. 1, Article ID e29541, 2012. View at Publisher · View at Google Scholar · View at Scopus